Skip to main content
Premium Trial:

Request an Annual Quote

King's Health Partners Teams with IDBS on Personalized Cancer Therapy Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – IDBS said today it will be providing its Oncology Research Information System translational medicine platform for the Integrated Cancer Centre at King's Health Partners.

The deal, the UK data management and analytics solutions firm said, is the first step in a five-year relationship that may eventually include all disease areas including cancer disorders and cardiovascular diseases.

King's Health Partners is a collaboration between King's College London University, King's College Hospital, Guy's and St. Thomas' and South London and the Maudsley NHS Foundation Trusts. It is one of five academic health sciences centers in the UK and brings together clinical and research expertise in both physical and mental health.

ORIS will allow King's Health Partners to develop personalized and targeted cancer therapies based on specific genetic and other characteristics of a patient. According to IDBS, ORIS is a "first of its kind" single cross-organizational platform that will bring together patient data for all King's Health Partners' cancer cases, accounting for a quarter of hospital beds in London.

One IT platform had never been able to manage such a comprehensive approach to cancer research, IDBS said, adding that ORIS will provide "a unique translational medicine hub, handling the complex analytical demands of translational research and improving the collaboration between" members of King's Health Partners.

Among the capabilities that IDBS will provide through ORIS and "associated organizational changes" are secure knowledge sharing of patient outcome data leading to improved cancer treatment; one secure searchable hub for clinical, diagnostic, pathological, sample, research and genomic-centric information integrated from multiple sources; secure information governance and procedures to ensure patient confidentiality; and comprehensive scientific and statistical analytics to support requirements across research, teaching, and clinical needs.

Financial and other terms of the deal were not disclosed.

"Despite all the progress medical science has made, many cancer patients are still treated with protocols indentified through a process of trial and error," said Peter Parker, head of the division of cancer studies and R&D lead for the Integrated Cancer Centre at King's Health Partners. "Critical to this effort is a new collaboration between the different research and healthcare organizations involved and, above all, access to relevant data and analytics to enable our multi-disciplinary research teams to deliver outcome-based therapies."

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.